Table 4.
Multivariable analyses of the predictors of self-reported infection.
| Variable | Clinical model (N = 139) | Clinical model with IgA (N = 73) | Clinical model with IgG (N = 104) | Clinical model with IgM (N = 83) | ||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | |
| Age | 0.96 (0.93–1.00) | 0.06 | 0.94 (0.88–1.01) | 0.07 | 0.94 (0.89–0.99) | 0.02 | 0.93 (0.88–0.99) | 0.02 |
| Female gender | 2.00 (0.93–4.30) | 0.08 | 2.48 (0.73–8.41) | 0.14 | 2.27 (0.91–5.71) | 0.08 | 2.27 (0.75–6.83) | 0.15 |
| Disease duration | 1.00 (0.95–1.06) | 0.98 | 1.09 (1.00–1.18) | 0.058 | 1.04 (0.98–1.12) | 0.21 | 1.05 (0.98–1.14) | 0.18 |
| Number of ocrelizumab doses | 0.97 (0.73–1.28) | 0.82 | 0.92 (0.56–1.52) | 0.76 | 0.96 (0.67–1.38) | 0.84 | 1.01 (0.66–1.55) | 0.97 |
| EDSS | 0.98 (0.81–1.18) | 0.80 | 1.09 (0.75–1.60) | 0.66 | 0.96 (0.74–1.25) | 0.75 | 1.11 (0.80–1.54) | 0.52 |
| IgA level | 0.37 (0.17–0.80) | 0.01 | ||||||
| IgG level | 0.81 (0.67–0.99) | 0.04 | ||||||
| IgM level | 0.56 (0.19–1.67) | 0.30 | ||||||
Bold values indicate statistical significance
CI confidence intervals, EDSS Expanded Disability Status Scale, OR odds ratio